A Phase 2 interventional study of 3D1002 (50 mg)(Phase IIa) and 3D1002 (100 mg)(Phase IIa) in Cancer Pain, sponsored by 3D Medicines. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by 3D Medicines · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing oxycodone in Cancer Pain — 1 open to participants now, 1 under way, none of them phase 3. Oxycodone · Cancer Pain.
Among the 10 studies testing oxycodone in Cancer Pain, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 2, and was the 10th registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →1 of the 10 studies testing oxycodone in Cancer Pain is open now.
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 177 is above the median of 63 across 236 interventional studies indexed under Cancer Pain.
Median enrollment 153 across the 10 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 7 most frequent:
3D Medicines is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
3D Medicines has 1 study filed under Cancer Pain — fewer than ten, so there is no comparison to draw.
1 of the studies testing oxycodone in Cancer Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT052650523D Medicines3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing oxycodone in Cancer Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
The investigational product in this study, 3D1002, is a selective antagonist of prostaglandin E2 receptor subtype 4 (EP4). The study is composed of two stages. Phase IIa stage is to assess the safety and efficacy of 3D1002 administered at doses of 50, 100 or 150 mg every 12 hour (q12h) for patients with moderate to severe cancer pain, and to determine the optimal recommended dose for further studies. Phase IIb stage is to evaluate the difference in the efficacy and safety of 3D1002 combined with OxyContin and OxyContin alone in treatment of patients with moderate to severe cancer pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3D1002 is given 50 mg twice a day for 2 weeks.
Drug: 3D1002 (50 mg)(Phase IIa)
3D1002 is given 100 mg twice a day for 2 weeks.
Drug: 3D1002 (100 mg)(Phase IIa)
3D1002 is given 150 mg twice a day for 2 weeks.
Drug: 3D1002 (150 mg)(Phase IIa)
3D1002 at recommended dose plus mimic OxyContin tables, will be given twice a day for 2 weeks.
Drug: 3D1002 monotherapy (Phase IIb)
OxyContin initiating at 10mg per dose plus mimic 3D1002 tablets, will be given twice a day for 2 weeks.
Drug: OxyContin monotherapy (Phase IIb)
3D1002 at recommended dose plus OxyContin initiating at 10 mg per dose, will be given twice a day for 2 weeks.
Drug: 3D1002 + OxyContin (Phase IIb)
1 tablet of 3D1002 per oral dose
2 tablets of 3D1002 per oral dose
3 tablets of 3D1002 per oral dose
3D1002 is administered at recommended dose with mimic OxyContin tablets.
OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
Sum of pain intensity difference in the Numeric Rating Scale (NRS) within 14 days after the first study drug treatment (SPID14)
①Average pain intensity is calculated daily for the past 24 hours using the NRS (0 = No pain, 10 = Worst pain imaginable). ②PID (pain intensity difference): Baseline pain intensity score (for the day prior to the day of randomization) minus pain intensity score at each given day.③SPID: the sum of the pain intensity difference generated daily from day 1 to the designated day.
Time frame: 1 to 14 days after receiving study treatment
Proportion of subjects who achieve effective pain control
Effective pain control: mean NRS score within 0-3 points and episode of breakthrough pain ≤ 2 times in 24 hours
Time frame: 1 to 14 days after receiving study treatment
Time to achieve effective pain control
Time frame: 1 to 14 days after receiving study treatment
Time-specific pain intensity difference(PID)
Time frame: 1 to 14 days after receiving study treatment
Sum of pain intensity difference (SPID) in the NRS within 3,5 and 7 days post-treatment
Time frame: from day 1 to 3, 5 and 7 after receiving study treatment, respectively
Time-specific subject self-rated pain relief based on Brief Pain Inventory Short Form (BPI-SF) Questionnaire Item 8
The pain relief is assessed daily for the past 24 hours based on the percentage of relief from baseline, ranging from 0 (no relief) to 100% (complete relief).
Time frame: 1 to 14 days after receiving study treatment
Sum of subject self-rated pain relief based on BPI-SF Questionnaire Item 8 within 3,5,7 and 14 days post-treatment
Time frame: from day 1 to 3, 5, 7 and 14 after receiving study treatment, respectively
Proportion of subjects with pain response over 7 and 14 days after treatment
Pain response: at least 30% and 50% decrease in pain intensity NRS score from baseline.
Time frame: 1 to 14 days after receiving study treatment
Time to pain response
Time frame: 1 to 14 days after receiving study treatment
The number of breakthrough pain episodes and rescue dose of immediate-release oxycodone over 7 and 14 days after treatment;
Time frame: 1 to 14 days after receiving study treatment
Time-specific oxycodone dose, including immediate-release oxycodone capsules and sustained-release oxycodone tablets (the latter is only applicable for phaseⅡb)
Time frame: 1 to 14 days after receiving study treatment
Total dose of oxycodone over 3, 7, and 14 days post-treatment
Time frame: 1 to 14 days after receiving study treatment
Patient's global impression of change (PGI-C) over 7 and 14 days after treatment (for phase IIb only)
PGI-C is a participant rated instrument to measure participant's change in overall status of general condition including pain on a 7-point scale, with 1 being "very much improved" and 7 being "very much worse".
Time frame: 1 to 14 days after receiving study treatment
Frequency and severity of adverse events during treatment
Time frame: 1 to 14 days after receiving study treatment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone
3D Medicines